Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (310)	8/7/2003 3:55:46 PM
From: Ian@SI	Respond to of 824

I don't recognize the name Pictet funds nor did I check to see whether or not this is a first filing... +++++++++++++++ Click to email this article Click to email this article Click to format this article for printing Click to format this article for printing advertisement Pictet Funds Reports A 5.4% Stake In Alexion Pharm DOW JONES NEWSWIRES WASHINGTON -- Pictet Funds reported a 5.4% stake in Alexion Pharmaceuticals Inc. (ALXN), according to a filing with the Securities and Exchange Commission Thursday. As of Tuesday, Pictet Funds beneficially owned 990,000 common shares of Alexion Pharmaceuticals, the filing said. Alexion Pharmaceuticals develops products to treat cardiovascular, autoimmune and neurologic diseases. A Schedule 13G denotes a passive investment stake in a company. Filers aren't required to provide a reason for any changes in stake and aren't required to detail any transactions.